Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in
detection and management through surgery, chemotherapy, radiotherapy, and …

Colorectal cancer (CRC) is the second leading cause of cancer death worldwide that is
attributed to gradual long‐term accumulation of both genetic and epigenetic changes. To …

Purpose The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as
first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of …

Personalized medicine (PM) or precision medicine in oncology is an emerging approach for
tumor treatment and prevention that takes into account inter-and intra-tumor variability in …

Simple Summary Colorectal cancer (CRC) is the third most common form of cancer in terms
of incidence and the second in terms of mortality worldwide. CRC develops over several …

Simple Summary This review aims to shed light on the proliferative markers important in the
everyday clinical management of colorectal cancer (CRC), ranging from simple methods of …

Cancer models, which are biologically representative of patient tumors, can predict the
treatment responses and help determine the most appropriate cancer treatment for …

Simple Summary Colorectal cancer (CRC) has been divided into four consensus molecular
subtypes (CMS) using the unsupervised clustering of bulk transcriptomic data. The CMS …

Colorectal cancer (CRC) is the second-most common malignant disease worldwide, and
metastasis is the main culprit of CRC-related death. Metachronous metastases remain to be …

Abstract HMGA2 (High Mobility Group AT-hook 2) has been reported to promote colorectal
cancer (CRC) development by regulating the transcription of target genes. It participates in …